Identification

Name
Carisoprodol
Accession Number
DB00395  (APRD00417)
Type
Small Molecule
Groups
Approved
Description

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)

Structure
Thumb
Synonyms
  • (+-)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
  • (1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
  • (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
  • 2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
  • 2-Methyl-2-propyltrimethylene carbamate isopropylcarbamate
  • Carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester
  • Carisoprodate
  • Carisoprodol
  • Carisoprodolum
  • Isobamate
  • Isomeprobamate
  • Isopropyl meprobamate
  • Isopropylmeprobamate
  • N-Isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate
  • Someprobamate
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SomaTablet250 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2007-09-012017-02-15Us
SomaTablet250 mg/1OralMeda Pharmaceuticals Ltd2007-09-01Not applicableUs
SomaTablet250 mg/1OralStat Rx USA2007-09-012018-02-08Us00037 2250 10 nlmimage10 bd1d5efa
SomaTablet350 mg/1OralMeda Pharmaceuticals Ltd1959-07-01Not applicableUs
SomaTablet250 mg/1OralRebel Distributors2007-09-01Not applicableUs
Soma Tablets 350mgTablet350 mgOralCarter Horner Corp.1962-12-312003-03-14Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarisoprodolTablet350 mg/1OralA S Medication Solutions1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralAidarex Pharmaceuticals LLC2010-08-30Not applicableUs
CarisoprodolTablet350 mg/1OralPreferreed Pharmaceuticals Inc.2015-05-01Not applicableUs
CarisoprodolTablet350 mg/1OralUnit Dose Services2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralAphena Pharma Solutions Tennessee, Inc.2014-02-20Not applicableUs
CarisoprodolTablet350 mg/1OralUnit Dose Services1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralStat Rx USA1996-01-242018-02-08Us
CarisoprodolTablet350 mg/1Oralbryant ranch prepack2015-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralA S Medication Solutions2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralProficient Rx LP2014-06-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralApotheca, Inc.2009-10-012016-10-13Us
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralRebel Distributors2009-10-01Not applicableUs
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralIngenus Pharmaceuticals Nj, Llc2011-06-09Not applicableUs
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralHeritage2011-03-31Not applicableUs
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralEon Labs, Inc.1996-04-25Not applicableUs
CARISOPRODOL and ASPIRINCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralRising Pharmaceuticals2010-01-07Not applicableUs
Carisoprodol, Aspirin and Codeine PhosphateCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1) + Codeine (16 mg/1)TabletOralIngenus Pharmaceuticals Nj, Llc2011-06-262018-04-07Us
Carisoprodol, Aspirin and Codeine PhosphateCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1) + Codeine phosphate (16 mg/1)TabletOralEon Labs, Inc.1996-04-162019-09-30Us
Carisoprodol, Aspirin and Codeine PhosphateCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1) + Codeine phosphate (16 mg/1)TabletOralRising Pharmaceuticals2010-01-10Not applicableUs
International/Other Brands
Carisoma / Gencari (Genovate) / Genesafe (Genovate) / Hiranin (Hwang's) / Listaflex (Finadiet) / Sanoma / Tensaprin (Newport)
Categories
UNII
21925K482H
CAS number
78-44-4
Weight
Average: 260.33
Monoisotopic: 260.173607266
Chemical Formula
C12H24N2O4
InChI Key
OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl N-(propan-2-yl)carbamate
SMILES
CCCC(C)(COC(N)=O)COC(=O)NC(C)C

Pharmacology

Indication

For the relief of discomfort associated with acute, painful, musculoskeletal conditions.

Associated Conditions
Pharmacodynamics

Carisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.

Mechanism of action

Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known.

TargetActionsOrganism
UGamma-aminobutyric acid receptor subunit alpha-1Not AvailableHuman
UGamma-aminobutyric acid receptor subunit beta-2Not AvailableHuman
UGamma-aminobutyric acid receptor subunit gamma-2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

60%

Metabolism

Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.

Route of elimination

Carisoprodol is eliminated by both renal and non-renal routes.

Half life

8 hours

Clearance
  • oral cl=0.772 L/hour/kg [Women]
  • oral cl=0.38 L/hour/kg [Men]
Toxicity

Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Carisoprodol can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Aceprometazine.Approved
Acetylsalicylic acidThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carisoprodol.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisoprodol.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carisoprodol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carisoprodol.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amperozide.Experimental
ApalutamideThe serum concentration of Carisoprodol can be decreased when it is combined with Apalutamide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.Approved, Investigational
ArmodafinilThe metabolism of Carisoprodol can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carisoprodol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Azaperone.Investigational, Vet Approved
AzelastineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Carisoprodol.Approved
BarbitalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Benzyl alcohol.Approved
BortezomibThe metabolism of Carisoprodol can be decreased when combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Bupivacaine.Approved, Investigational
BuprenorphineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carisoprodol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Carisoprodol.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carisoprodol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Carisoprodol can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Carfentanil.Illicit, Investigational, Vet Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carisoprodol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Carisoprodol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carisoprodol.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carisoprodol.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carisoprodol.Approved
CholecalciferolThe metabolism of Carisoprodol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Carisoprodol can be decreased when combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Carisoprodol can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Carisoprodol.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Carisoprodol.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carisoprodol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Carisoprodol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carisoprodol.Approved
CocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Carisoprodol.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapoxetine.Investigational
DelavirdineThe metabolism of Carisoprodol can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Carisoprodol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Carisoprodol.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carisoprodol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carisoprodol.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carisoprodol.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Carisoprodol is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Carisoprodol can be decreased when combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Carisoprodol can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Carisoprodol can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Carisoprodol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carisoprodol.Approved, Investigational
EthanolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Carisoprodol can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carisoprodol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Carisoprodol can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Carisoprodol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carisoprodol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carisoprodol.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Carisoprodol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Carisoprodol can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carisoprodol.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Carisoprodol.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Carisoprodol can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Hexobarbital.Approved
HydrocodoneCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Carisoprodol can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Carisoprodol.Approved, Vet Approved
IsoniazidThe metabolism of Carisoprodol can be decreased when combined with Isoniazid.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisoprodol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Carisoprodol can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carisoprodol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lidocaine.Approved, Vet Approved
Lithium cationThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lithium.Experimental
LobeglitazoneThe metabolism of Carisoprodol can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Carisoprodol can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Carisoprodol can be increased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carisoprodol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lormetazepam.Approved
LorpiprazoleThe therapeutic efficacy of Carisoprodol can be increased when used in combination with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carisoprodol.Approved
LuliconazoleThe serum concentration of Carisoprodol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Carisoprodol can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Carisoprodol can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Carisoprodol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carisoprodol.Approved
MethotrimeprazineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methylphenobarbital.Approved
MetyrosineCarisoprodol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Investigational
MirtazapineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Carisoprodol can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Carisoprodol can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Carisoprodol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carisoprodol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Carisoprodol can be decreased when combined with Nelfinavir.Approved
NicardipineThe metabolism of Carisoprodol can be decreased when combined with Nicardipine.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carisoprodol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Carisoprodol.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carisoprodol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Carisoprodol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Opium.Approved, Illicit
OrphenadrineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carisoprodol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisoprodol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carisoprodol.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carisoprodol.Approved
PantoprazoleThe metabolism of Carisoprodol can be decreased when combined with Pantoprazole.Approved
ParaldehydeCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carisoprodol.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
PerazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carisoprodol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carisoprodol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carisoprodol.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Carisoprodol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Carisoprodol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.Approved
PramipexoleCarisoprodol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Carisoprodol can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Carisoprodol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Carisoprodol is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Carisoprodol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carisoprodol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carisoprodol.Approved, Investigational
RifampicinThe metabolism of Carisoprodol can be increased when combined with Rifampicin.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Romifidine.Vet Approved
RopiniroleCarisoprodol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ropivacaine.Approved
RotigotineCarisoprodol may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Carisoprodol can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Carisoprodol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carisoprodol.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Carisoprodol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carisoprodol.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
St. John's WortThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe metabolism of Carisoprodol can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sultopride.Experimental
SuvorexantCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Carisoprodol.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrodotoxin.Investigational
ThalidomideCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carisoprodol.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carisoprodol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Carisoprodol can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carisoprodol.Approved, Withdrawn
TopiramateThe metabolism of Carisoprodol can be decreased when combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carisoprodol.Approved, Investigational
TranylcypromineThe metabolism of Carisoprodol can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Carisoprodol.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Carisoprodol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carisoprodol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zolazepam.Vet Approved
ZolpidemCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Carisoprodol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Carisoprodol can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carisoprodol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc.

General References
  1. Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. [PubMed:15530999]
  2. Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed:15276195]
  3. Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. [PubMed:8322081]
External Links
Human Metabolome Database
HMDB0014539
KEGG Drug
D00768
KEGG Compound
C07927
PubChem Compound
2576
PubChem Substance
46506377
ChemSpider
2478
ChEBI
3419
ChEMBL
CHEMBL1233
PharmGKB
PA448809
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Carisoprodol
ATC Codes
M03BA52 — Carisoprodol, combinations excl. psycholepticsM03BA02 — CarisoprodolM03BA72 — Carisoprodol, combinations with psycholeptics
FDA label
Download (84.9 KB)
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentLower Back Pain1

Pharmacoeconomics

Manufacturers
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Able laboratories inc
  • Actavis totowa llc
  • Advent pharmaceuticals inc
  • Aurobindo pharma ltd
  • Concord laboratories inc
  • Corepharma llc
  • Mutual pharmaceutical co inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Schering corp sub schering plough corp
Packagers
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Chattem Chemicals Inc.
  • Corepharma LLC
  • Darby Dental Supply Co. Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Eon Labs
  • Gm Pharmaceuticals Inc.
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Meda AB
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
  • Wallace Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral350 mg/1
TabletOral
TabletOral250 mg/1
TabletOral350 mg
Prices
Unit descriptionCostUnit
Soma 350 mg tablet5.75USD tablet
Soma Compound 200-325 mg tablet4.58USD tablet
Soma 250 mg tablet3.24USD tablet
Carisoprodol powder1.17USD g
Carisoprodol 350 mg tablet0.57USD tablet
Flexall plus gel0.08USD g
Flexall 16% gel0.06USD g
Flexall 7% gel0.05USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)89-91Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc.
water solubility300 mg/L (at 25 °C)MERCK INDEX (1996)
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.792 mg/mLALOGPS
logP1.76ALOGPS
logP1.92ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)15.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.65 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability28.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9626
Blood Brain Barrier+0.9679
Caco-2 permeable-0.5533
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.8014
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.9519
CYP450 2C9 substrateNon-substrate0.9041
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6418
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8659
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6872
BiodegradationNot ready biodegradable0.973
Rat acute toxicity2.3261 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9957
hERG inhibition (predictor II)Non-inhibitor0.9362
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9200000000-7ee2bc67a583d40d99b8
Mass Spectrum (Electron Ionization)MSsplash10-0a4l-9200000000-84ceb4ca447a62939b63
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-4910000000-0fe5eef3c39360c36d38
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-9300000000-94d7b1adea0d831c0950
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dj-9100000000-a99d65f53726ca3b6116
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-618eb5a23da29ec51cb6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-d2d07fc2a5972fd4e9f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-007521fa65c254bad2b6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-056r-1920000000-df362ad4c912b7d0fb43

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Carbamate esters
Alternative Parents
Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
carbamate ester (CHEBI:3419)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:18